Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H
Biological and Chemical Research, Boehringer Ingelheim Pharma KG, 88397, Biberach, Germany.
Eur J Pharmacol. 2000 Jul 21;400(2-3):313-9. doi: 10.1016/s0014-2999(00)00407-6.
The present study was performed in order to characterise calcitonin gene-related peptide (CGRP) receptor subtypes in rat left atrium and vas deferens by using [R-(R*, S*)]-N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]pentyl ]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1, 4-dihydro-2-oxo-3(2H)-quinazolinyl)-,1-Piperidinecarboxamide (BIBN4096BS), a novel CGRP receptor antagonist. When CGRP was used as an agonist, BIBN4096BS exhibited an almost 10-fold higher affinity for CGRP receptors in rat left atrium compared to those in the vas deferens, indicating that CGRP acts through different CGRP receptor subtypes in these two tissues. In addition, BIBN4096BS was almost 10-fold more potent in antagonizing [Cys(Et)(2,7)]hCGRPalpha and human adrenomedullin-induced responses than CGRP-induced responses in rat vas deferens. This might indicate receptor heterogeneity in rat vas deferens. Accordingly, the present work provides first experimental evidence that the rat vas deferens contains two CGRP-like receptor subtypes. Namely, the CGRP(2) receptor and a "novel" receptor that possesses low efficacy for CGRP and that is selectively stimulated by [Cys(Et)(2,7)]hCGRP or adrenomedullin and which can be blocked with high affinity by BIBN4096BS.
本研究旨在通过使用新型降钙素基因相关肽(CGRP)受体拮抗剂[R-(R*,S*)]-N-[2-[[5-氨基-1-[[4-(4-吡啶基)-1-哌嗪基]羰基]戊基]氨基]-1-[(3,5-二溴-4-羟基苯基)甲基]-2-氧代乙基]-4-(1,4-二氢-2-氧代-3(2H)-喹唑啉基)-1-哌啶甲酰胺(BIBN4096BS)来表征大鼠左心房和输精管中的CGRP受体亚型。当使用CGRP作为激动剂时,与输精管中的CGRP受体相比,BIBN4096BS对大鼠左心房中的CGRP受体表现出近10倍的更高亲和力,表明CGRP在这两种组织中通过不同的CGRP受体亚型发挥作用。此外,在拮抗[Cys(Et)(2,7)]hCGRPα和人肾上腺髓质素诱导的反应方面,BIBN4096BS在大鼠输精管中比CGRP诱导的反应几乎强10倍。这可能表明大鼠输精管中存在受体异质性。因此,本研究首次提供实验证据表明大鼠输精管含有两种CGRP样受体亚型。即CGRP(2)受体和一种对CGRP效力低的“新型”受体,该受体可被[Cys(Et)(2,7)]hCGRP或肾上腺髓质素选择性激活,并可被BIBN4096BS高亲和力阻断。